The VENTANA PATHWAY anti-HER2/neu (4B5) rabbit monoclonal primary antibody has been approved by the FDA as the first companion diagnostic test to identify patients with low HER2 BC for ADCs [31]. Here, ERBB2 is linked to breast cancer.